Kerecis Omega3 Fish Skin Wound Grafts Recruit Significantly More Cells than a Leading Amnion Membrane Wound Treatment Brand.
Results of laboratory studies announced at the Symposium for Advancement of Wound Care
Las Vegas, NV, September 25, 2015 – Kerecis, the company using fish skin to heal human wounds and tissue damage, will present recent laboratory results, demonstrating that significantly more cells proliferate into acellular fish skin than a leading amnion membrane wound treatment brand on the market. These findings are the results of research done at the Center for System Biology at the University of Iceland. The presentation will take place during Kerecis’ U.S. market launch at the Symposium for the Advancement of Wound Care (SAWC) held September 26 ‒ 28 at Caesars Palace in Las Vegas. See us at Booth 227.
“Amnion membrane products have enjoyed increased clinical adoption in recent years. However, laboratory results show that, over time, more cells migrate into fish skin than into amnion membrane products. This supports feedback we have received from wound treatment specialists about the superior clinical outcome enjoyed by a cellular fish skin,” said Dr. Baldur Tumi Baldursson, Kerecis medical director.
Specifically, Kerecis will present scientific results that show:
150% more cells migrate into Kerecis Omega3 acellular fish skin than into a leading amnion membrane wound treatment brand.
Kerecis Omega3 acellular fish skin effectively recruits cells and stem cells into its structure where they support normal physiological healing of tissue damage in essential ways.
In a randomized controlled human study on 162 wounds, those treated with Kerecis Omega3 acellular fish skin closed significantly faster than wounds treated with a competitive product, with up to twice as many wounds closed at the study time points.